top of page
  • LinkedIn
  • Facebook
  • Twitter

Life-saving, nanoparticle-based therapies for septic shock and severe blood loss

About our Phase 3 Trial

 

Vivacelle Bio Recently Initiated a Phase 3 Trial for its Lead Asset - VBI-S - to Treat Patients with Hypovolemia Due to Septic Shock

 

The open-label, randomized, controlled Phase 3 trial is enrolling 40 septic shock patients across seven planned sites in the U.S., including some of the largest septic shock treatment centers in the country. The study is designed to compare VBI-S and standard of care (SOC) to SOC alone in a 1:1 ratio.

 

The primary endpoint for the trial is an increase in the mean arterial blood pressure (MAP) by at least 10 mmHg with a target of 60-65 mmHg. Patients in the Phase 3 trial will have failed attempts to raise blood pressure to a survivable level using standard fluids and will be on vasopressors which may produce severe life-threatening complications.

 [CM1]Need to update this stating that the trial has been initiated.

New Paradigm in Fluid Resuscitation

Millions of Lives

Substantial Medical Need & Market Opportunity

Sepsis is a leading cause of death killing 11M globally including 3.4M children

 

Innovative Platform

Phospholipid Nanoparticles – VBI-S and VBI-1 – are designed to restore intravascular volume and redistribute overproduced nitric oxide to treat relative and absolute hypovolemia resulting in reversal of hypotension and organ failure in patients who are septic or have had severe blood loss.

A New Paradigm

For the treatment of absolute and relative hypovolemia for life-saving intervention in septic shock and severe blood loss 

Vivacelle Bio

Recent Feature in The Lancet Journal

Our team is composed of dedicated doctors and business leaders focusing on advancing the field of shock treatments to save the lives of millions.

Meet the Team

Cuthbert Simpkins

MD, FACS

CIO, Founder & President

Harven DeShield

PhD, JD, Msc

CEO, Co-Founder

Krishna Talluri

MD

CMO, Co-Founder

Mukesh Kumar
PhD, RAC

SVP, Regulatory Affairs

What is Hypovolemia?

bottom of page